68.43

3.55% -2.52

After Hours: 69.41 0.98 +1.43%

Liquidia Corp (LQDA)

Overview News Price History Option Chain Financials Discussions Forecast

Liquidia Corp stock is traded at $68.43, with a volume of 967.32K. It is down -3.55% in the last 24 hours and down -2.92% over the past month. Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Previous Close:

$70.95

Open:

$71.6

24h Volume:

967.32K

Relative Volume:

0.66

Market Cap:

$6.13B

Revenue:

$288.07M

Net Income/Loss:

$22.31M

P/E Ratio:

483.26

EPS:

0.1416

Net Cash Flow:

$41.15M

1W Performance:

+2.32%

1M Performance:

-2.92%

6M Performance:

+86.92%

1Y Performance:

+204.81%

1-Day Range:

$67.55

$71.81

1-Week Range:

$65.74

$71.81

52-Week Range:

$21.14

$93.61

Liquidia Corp Stock (LQDA) Company Profile

Name

Liquidia Corp

Sector

Healthcare (1067)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

919.328.4400

Address

419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC

Employee

216

Twitter

@Liquidia_Inc

Next Earnings Date

2026-11-02

Latest SEC Filings

LQDA's Discussions on Twitter

Compare LQDA vs TAK, TEVA, HLN, ZTS, VTRS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LQDA Liquidia Corp	68.43	6.13B	288.07M	22.31M	41.15M	0.1416
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Liquidia Corp Stock (LQDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Aug-15-25	Resumed	Jefferies	Buy
May-19-25	Downgrade	Oppenheimer	Perform → Underperform
Dec-20-24	Initiated	Wells Fargo	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy
Sep-19-22	Resumed	Wedbush	Underperform
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform
Jul-22-22	Initiated	Ladenburg Thalmann	Buy
May-31-22	Initiated	BTIG Research	Buy
May-26-22	Initiated	BofA Securities	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform
Aug-20-18	Initiated	Jefferies	Buy
Aug-20-18	Initiated	Needham	Buy

View All

Liquidia Corp Stock (LQDA) Latest News

Sep 25, 2026

LQDA News | LIQUIDIA CORP (NASDAQ:LQDA) - ChartMill

Sep 25, 2026

Sep 24, 2026

Is It Too Late to Buy Liquidia Corp (LQDA) After 5.1% Rally? GF Value Says Undervalued - GuruFocus

Sep 24, 2026

Form 144 LIQUIDIA CORPORATION For: 22 September By Investing.com - Investing.com Canada

Sep 22, 2026

Sep 20, 2026

Liquidia (NASDAQ:LQDA) Rating Increased to Buy at Wall Street Zen - MarketBeat

Sep 20, 2026

Sep 19, 2026

Liquidia (NASDAQ:LQDA): Strong Growth Paired With Technical Setup Quality - ChartMill

Sep 19, 2026

Sep 16, 2026